Whole Genome Messenger RNA Profiling Identifies a Novel Signature to Predict Gastric Cancer Survival
Jin Dai,Zhe-Xuan Li,Yang Zhang,Jun-Ling Ma,Tong Zhou,Wei-Cheng You,Wen-Qing Li,Kai-Feng Pan
DOI: https://doi.org/10.14309/ctg.0000000000000004
2019-01-01
Clinical and Translational Gastroenterology
Abstract:OBJECTIVES: Molecular prognostic biomarkers for gastric cancer (GC) are still limited. We aimed to identify potential messenger RNAs (mRNAs) associated with GC prognosis and further establish an mRNA signature to predict the survival of GC based on the publicly accessible databases. METHODS: Discovery of potential mRNAs associated with GC survival was undertaken for 441 patients with GC based on the Cancer Genome Atlas (TCGA), with information on clinical characteristics and vital status. Gene ontology functional enrichment analysis and pathway enrichment analysis were conducted to interrogate the possible biological functions. We narrowed down the list of mRNAs for validation study based on a significance level of 1.00 × 10 −4 , also integrating the information from the methylation analysis and constructing the protein–protein interaction network for elucidating biological processes. A total of 54 mRNAs were further studied in the validation stage, using the Gene Expression Omnibus (GEO) database (GSE84437, n = 433). The validated mRNAs were used to construct a risk score model predicting the prognosis of GC. RESULTS: A total of 13 mRNAs were significantly associated with survival of GC, after the validation stage, including DCLK1 , FLRT2 , MCC , PRICKLE1 , RIMS1 , SLC25A15 , SLCO2A1 , CDO1 , GHR , CD109 , SELP , UPK1B , and CD36 . Except CD36 , DCLK1 , and SLCO2A1 , other mRNAs are newly reported to be associated with GC survival. The 13 mRNA-based risk score had good performance on distinguishing GC prognosis, with a higher score indicating worse survival in both TCGA and GEO datasets. CONCLUSIONS: We established a 13-mRNA signature to potentially predict the prognosis of patients with GC, which might be useful in clinical practice for informing patient stratification.